Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma

References

• Dunussi-JoannopoulosKDranoffGWeinsteinHJFerraraJLBiererBECroopJMGene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccinesBlood19989112222309414288
   PubMed Web of Science ®Google Scholar
• SmallEJSacksNNemunaitisJGranulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancerClin Cancer Res200713133883389117606721
   PubMedGoogle Scholar
• MaioMFonsattiELamajEVaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cellsCancer Immunol Immunother200251191411845255
   PubMedGoogle Scholar
• SalgiaRLynchTSkarinAVaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinomaJ Clin Oncol200321462463012586798
   PubMed Web of Science ®Google Scholar
• SoifferRHodiFSHaluskaFVaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaJ Clin Oncol200321173343335012947071
   PubMed Web of Science ®Google Scholar
• NemunaitisJStermanDJablonsDGranulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancerJ Natl Cancer Inst200496432633114970281
   PubMedGoogle Scholar
• ZhangXShiXLiJA novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancerJ Urol201218731071107922266013
   PubMed Web of Science ®Google Scholar
• Moret-TatayIDíazJMarcoFMCrespoAAliñoSFComplete tumor prevention by engineered tumor cell vaccines employing nonviral vectorsCancer Gene Ther2003101288789714712315
   PubMedGoogle Scholar
• MiguelAHerreroMJSendraLComparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine modelToxins20124111058108123202306
   PubMedGoogle Scholar
• MiguelAHerreroMJSendraLComparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccinesCancer Gene Ther2013201057658123969885
   PubMedGoogle Scholar
• Moret-TatayISanmartínIMarcoFMDíazJAliñoSFNonviral therapeutic cell vaccine mediates potent antitumor effectsVaccine200624183937394516530895
   PubMedGoogle Scholar
• GuoCManjiliMHSubjeckJRSarkarDFisherPBWangXYTherapeutic cancer vaccines: past, present, and futureAdv Cancer Res201311942147523870514
   PubMed Web of Science ®Google Scholar
• IseWKohyamaMNutschKCTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanismsNat Immunol201011212913520037585
   PubMed Web of Science ®Google Scholar
• WingKYamaguchiTSakaguchiSCell-autonomous and non-autonomous roles of CTLA-4 in immune regulationTrends Immunol201132942843321723783
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• JosefowiczSZLuLFRudenskyAYRegulatory T cells: mechanisms of differentiation and functionAnnu Rev Immunol20123053156422224781
   PubMed Web of Science ®Google Scholar
• WuYBordeMHeissmeyerVFOXP3 controls regulatory T cell function through cooperation with NFATCell2006126237538716873067
   PubMed Web of Science ®Google Scholar
• Franco-MolinaMAMiranda-HernándezDFMendoza-GamboaESilencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environmentOnco Targets Ther2016924325326834483
   PubMed Web of Science ®Google Scholar
• de AlmagroMCComaSNoéVCiudadCJPolypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genesJ Biol Chem200928417115791158919261618
   PubMedGoogle Scholar
• de AlmagroMCMenciaNNoéVCiudadCJCoding polypurine hairpins cause target-induced cell death in breast cancer cellsHum Gene Ther201122445146320942657
   PubMedGoogle Scholar
• RodríguezLVillalobosXDakhelSPolypurine reverse Hoog-steen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivoBiochem Pharmacol201386111541155424070653
   PubMedGoogle Scholar
• VillalobosXRodríguezLPrévotJOleagaCCiudadCJNoéVStability and immunogenicity properties of the gene-silencing poly-purine reverse Hoogsteen hairpinsMol Pharm201411125426424251728
   PubMedGoogle Scholar
• GuillemVMTormoMRevertFPolyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell linesJ Gene Med20024217018211933218
   PubMedGoogle Scholar
• GuillemVMAliñoSFTransfection pathways of nonspecific and targeted PEI-polyplexesGene Ther Mol Biol20048369384
   Google Scholar
• ZhangHHFeiRXieXWSpecific suppression in regulatory T cells by Foxp3 siRNA contributes to enhance the in vitro anti-tumor immune response in hepatocellular carcinoma patientsBeijing Da Xue Xue Bao200941331331819727215
   PubMedGoogle Scholar
• WardAJNorrbomMChunSBennettCFRigoFNonsense-mediated decay as a terminating mechanism for antisense oligonucleotidesNucleic Acids Res20144295871587924589581
   PubMed Web of Science ®Google Scholar
• BurdickADSciabolaSMantenaSRSequence motifs associated with hepatotoxicity of locked nucleic acid – modified antisense oligonucleotidesNucleic Acids Res20144284882489124550163
   PubMedGoogle Scholar
• YangBYuRLTuoSAntisense oligonucleotide against hTERT (Cantide) inhibits tumor growth in an orthotopic primary hepatic lymphoma mouse modelPLoS One201277e4146722848504
   PubMedGoogle Scholar
• HeemskerkHde WinterCvan KuikPPreclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse modelMol Ther20101861210121720407428
   PubMed Web of Science ®Google Scholar
• GaudetDAlexanderVJBakerBFAntisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemiaN Engl J Med2015373543844726222559
   PubMed Web of Science ®Google Scholar
• SugiharaCFreemantleNHughesSGFurnissSSulkeNThe effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-upJ Interv Card Electrophysiol2015431919825711952
   PubMedGoogle Scholar
• BüllerHRBethuneCBhanotSFactor XI antisense oligonucleotide for prevention of venous thrombosisN Engl J Med2015372323224025482425
   PubMed Web of Science ®Google Scholar
• GavinMARasmussenJPFontenotJDFoxp3-dependent programme of regulatory T-cell differentiationNature2007445712977177517220874
   PubMed Web of Science ®Google Scholar
• HoriSNomuraTSakaguchiSControl of regulatory T cell development by the transcription factor Foxp3Science200329956091057106112522256
   PubMed Web of Science ®Google Scholar
• MarsonAKretschmerKFramptonGMFoxp3 occupancy and regulation of key target genes during T-cell stimulationNature2007445713093193517237765
   PubMedGoogle Scholar
• ZhengYJosefowiczSZKasAChuTTGavinMARudenskyAYGenome-wide analysis of Foxp3 target genes in developing and mature regulatory T cellsNature2007445713093694017237761
   PubMed Web of Science ®Google Scholar
• OnoMYaguchiHOhkuraNFoxp3 controls regulatory T-cell function by interacting with AML1/Runx1Nature2007446713668568917377532
   PubMed Web of Science ®Google Scholar
• WingKOnishiYPrieto-MartinPCTLA-4 control over Foxp3+ regulatory T cell functionScience2008322589927127518845758
   PubMed Web of Science ®Google Scholar
• MiyaraMYoshiokaYKitohAFunctional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factorImmunity200930689991119464196
   PubMed Web of Science ®Google Scholar
• KmieciakMGowdaMGrahamLHuman T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor functionJ Transl Med200922789
   Google Scholar
• AllanSECromeSQCrellinNKActivation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine productionInt Immunol200719434535417329235
   PubMed Web of Science ®Google Scholar
• GavinMATorgersonTRHoustonESingle-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell developmentProc Natl Acad Sci U S A2006103176659666416617117
   PubMed Web of Science ®Google Scholar
• TranDQRamseyHShevachEMInduction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotypeBlood200711082983299017644734
   PubMedGoogle Scholar
• WangJIoan-FacsinayAvan der VoortEIHuizingaTWToesRETransient expression of FOXP3 in human activated nonregulatory CD4+ T cellsEur J Immunol200737112913817154262
   PubMed Web of Science ®Google Scholar
• van ElsasAHurwitzAAAllisonJPCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med1999190335536610430624
   PubMed Web of Science ®Google Scholar
• SimpsonTRLiFMontalvo-OrtizWFc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaJ Exp Med201321091695171023897981
   PubMed Web of Science ®Google Scholar
• SutmullerRPvan DuivenvoordeLMvan ElsasASynergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responsesJ Exp Med2001194682383211560997
   PubMed Web of Science ®Google Scholar
• TsaiBYSuenJLChiangBLLentiviral-mediated Foxp3 RNAi suppresses tumor growth of regulatory T cell-like leukemia in a murine tumor modelGene Ther201017897297920357829
   PubMedGoogle Scholar
• GregorPDWolchokJDFerroneCRCTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsVaccine20042213–141700170815068853
   PubMed Web of Science ®Google Scholar
• PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A2003100148372837712826605
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• MocellinSNittiDTherapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccinesMed Res Rev200828341344417694549
   PubMedGoogle Scholar